Beyond gastroparesis, other serious conditions like ileus and bowel obstruction are also being linked to these medications
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial Summary: This Phase 1b trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of co-administering once-weekly subcutaneous cagrilintide (at various doses) with semaglutide 2.4 mg in participants for weight management
GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
I never worried about my size, assuming I had a fast metabolism to thank
Two entirely separate physiological processes
This article/blog/episode does not provide investment advice, and is intended for informational and entertainment purposes only